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Mutations in a Thiamine-Transporter Gene  
and Wernicke’s-like Encephalopathy
To the Editor: We report on two previously 
healthy Japanese brothers with a newly discovered 
recessively inherited syndrome similar to Wer-
nicke’s encephalopathy that developed in the sec-
ond decade of life; this syndrome was manifested 
clinically as thiamine-responsive diplopia and 
ptosis without serum thiamine deficiency. The 
patients had complex partial seizures resulting 
in status epilepticus. The administration of high-
dose thiamine (up to 600 mg) improved the sei-
zures within 24 hours, although the ophthalmo-
plegia, nystagmus, and ataxia continued for 
several weeks. There were no extrapyramidal fea-
tures. Magnetic resonance imaging (MRI) of the 
brain showed high-intensity signals in the bilat-
eral medial thalamus and periaqueductal region 
on fluid-attenuated inversion recovery images 
(Fig. 1A); these signals were characteristic of 
findings in Wernicke’s encephalopathy and be-
came normal within 1 month after treatment. 
Interviews of the patients’ relatives confirmed 
that there was no consanguinity in their parents. 
Subacute ophthalmoplegia with nystagmus and 
ataxia occurred repeatedly within several months 
after the discontinuation of 100 mg of thiamine 
per day. There was no history of chronic alcohol-
ism in either patient. Korsakoff’s psychosis did 
not occur even after long periods of Wernicke’s-
like symptoms.
The clinical and imaging features resembling 
Wernicke’s encephalopathy in these patients sug-
gested that the syndrome was caused by a ge-
netic disorder of thiamine metabolism.1 Genomic 
analysis of SLC19A3 encoding human thiamine 
transporter 2 (hTHTR2)2,3 revealed that the pa-
tients were compound heterozygotes for the K44E 
and E320Q mutations; these mutations were not 
present among 192 ethnically matched control 
subjects (Fig. 1B and 1C). Gene-expression analy-
ses of mammalian culture cells showed the ma-
jority of the K44E mutant to be impaired in intra-
cellular transport while remaining normal in the 
endoplasmic reticulum. The E320Q mutant was 
identical in cell-surface localization to the wild-
type protein (Fig. 1D), whereas intracellular thia-
mine uptake activity was decreased significantly 
(Fig. 1E). High expression of SLC19A3 RNA in the 
thalamus (Fig. 1F) may explain the selective tha-
lamic lesions on MRI.
Mutation of SLC19A3 causes a biotin-responsive 
basal-ganglia disease characterized by subacute 
encephalopathy with rigidity and dystonia. Biotin 
is effective and thiamine is ineffective in treat-
ing this childhood-onset disease.4,5 The features 
of this process on MRI are bilateral necrotic le-
sions in the caudate heads; this is markedly dif-
ferent from the locus of lesions in the disease we 
describe.4 The absence of serum thiamine defi-
ciency and the efficacy of high-dose thiamine in 
our patients suggest that dysfunction of hTHTR2 
may induce the expression of another human thia-
mine transporter 1–encoded gene called SLC19A2, 
thereby increasing intracellular thiamine trans-
port in enterocytes and neuronal cells. The iden-
tification of this syndrome provides insight into 
the thiamine metabolism associated with Wer-
nicke’s encephalopathy in humans and suggests 
that the mechanism of Korsakoff’s psychosis may 
be independent of these thiamine pathways.
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Figure 1. Analyses of Data from Two Brothers with a Wernicke’s-like Encephalopathy.
Panel A shows the brain MRI scans in the older brother on hospitalization for status epilepticus with external ophthalmoplegia at 36 
years of age. The scan on the left shows high-intensity signals in the periaqueductal region, and the scan on the right shows high-inten-
sity signals in the bilateral medial thalamus. Panel B shows the results of electrophoresis of directly sequenced SLC19A3 polymerase-
chain-reaction products amplified from the leukocyte DNA of an older brother of the two patients. The sequence analyses showed an 
A→G substitution at nucleotide position 218 in exon 2 resulting in a substitution of lysine at codon 44 with glutamic acid and a G→C 
substitution at nucleotide position 1047 in exon 3 resulting in a substitution of glutamic acid at codon 320 with glutamine. Sequence 
analyses of genes associated with thiamine metabolism, including TKT, PDHA2, OGDH, DLD, and SLC19A2, showed no genetic varia-
tion involving newly discovered benign polymorphisms. Panel C shows the results of the analysis of the restriction-fragment–length 
polymorphisms of the family. In the pedigree portion of th  figure, solid symbol  d ote affected family members and half-solid sym-
bols indicate carriers of the mutation. Digestion of a mutant sequence for the K44E or E320Q mutation resulted in 300-bp and 207-bp 
fragments, respectively. The patients (lanes 3 and 4) had two fragments that indicated compound heterozygosity for K44E and E320Q. 
The father was heterozygous for E320Q (lane 1), whereas the mother was heterozygous for K44E (lane 2). Panel D shows cellular local-
izations of wild-type protein and K44E and E320Q mutants by means of immunofluorescence assay. SLC19A3 complementary DNA 
(cDNA) was subcloned into PcDNA6.2/GW/D-TOPO (Invitrogen) with a C-terminal V5 epitope tag. Chinese hamster ovary (CHO) cells 
were transiently transfected with wild-type, K44E, or E320Q SLC19A3 cDNA and were processed for immunofluorescence. The cells were 
labeled with the use of antibodies against V5 or resident protein disulfide isomerase (PDI) in the endoplasmic reticulum. Images in the 
Merge column are composite overlays of the V5 and PDI images. Panel E shows intracellular [3H]-thiamine uptake by CHO cell lines sta-
bly expressing wild-type protein or K44E or E320Q mutants. The results are expressed in counts per minute as the means of uptake val-
ues obtained from three independent experiments. I bars represent standard errors. P<0.01 for the comparisons of wild-type protein 
with K44E and E320Q. Panel F shows the SLC19A3 RNA levels in different areas of the human brain calculated with the use of a control 
messenger RNA–plasmid standard curve, then normalized to glyceraldehyde-3-phosphate dehydrogenase. The results are expressed as 
the means from three independent experiments. I bars represent standard errors.
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